adegramotide + nelatimotide

Adegramotide + nelatimotide is a fixed-dose combination of two synthetic peptides, each derived from the Wilms’ tumor 1 (WT1) antigen. Developed as an intradermally administered cancer peptide vaccine (also known as DSP-7888 Emulsion or ombipepimut-S), this formulation is designed to stimulate both WT1-specific cytotoxic T lymphocytes (CTLs, via nelatimotide) and helper T lymphocytes (HTLs, via adegramotide), thereby enhancing immune-mediated antitumor activity, particularly against WT1-positive hematologic malignancies and solid tumors. Clinical and preclinical studies show that the combination, compared to nelatimotide alone, more effectively induces interferon-gamma-secreting, functional tumor-infiltrating CD8+ T cells even within immunosuppressive tumor microenvironments. The combination has been evaluated in combination with checkpoint inhibitors (e.g., anti-PD-1 drugs) and has been explored as a therapy for myelodysplastic syndromes, glioblastoma, and other cancers. The developers are Sumitomo Pharma and collaborators including Osaka University, Kyoto Prefectural University of Medicine, Sumitomo Pharma America, and Wakayama Medical University. The FDA granted orphan drug designation for myelodysplastic syndromes and brain cancer, although development for most indications has been discontinued[1][2][3][4][5][6][7].

Brand names

Ombipepimut-S Emulsion

Other names

WT1 cancer peptide vaccineWT-1 cancer peptide vaccineWT 1 cancer peptide vaccineDSP 7888 EmulsionDSP7888 EmulsionDSP-7888 Emulsionadegramotide and nelatimotide